Aging Clinical and Experimental Research

, Volume 15, Issue 4, pp 271–283 | Cite as

Injectable bisphosphonates in the treatment of postmenopausal osteoporosis

  • Leonardo Sartori
  • Silvano Adami
  • Paolo Filipponi
  • Gaetano Crepaldi
Review Article
First Online:
Received:
Accepted:

Abstract

Osteoporosis is a “silent” disease and the patient has usually no clue of it until the occurrence of a fragility fracture. Prevention requires a continuous daily treatment that could be uncomfortable to the patient. Besides the recently introduced weekly oral schedules, injectable bisphosphonates have often been used as an off-label option to ameliorate compliance. In general, although with different efficiency, almost all injectable bisphosphonates can improve bone mineral density and suppress bone resorption markers. The effect of intravenous infusions of bisphosphonates are, to a large extent, similar to equivalent intramuscular administrations, but doses and dosing intervals represent the critical issues. Pain at the injection site and acute phase reactions are relatively common to intramuscular clodronate and intravenous infusions of nitrogen-containing bisphosphonates, respectively. Under certain circumstances, intermittent treatment with injectable bisphosphonates might represent a feasible alternative when compliance is at risk.

Keywords

Bisphosphonate dosage clodronate ibandronate injectable bisphosphonates neridronate pamidronate patient compliance treatment of osteoporosis zoledronate 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women. The OFELY study. J Bone Miner Res 2000; 15: 1526–36.CrossRefGoogle Scholar
  2. 2.
    Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478–87.PubMedCrossRefGoogle Scholar
  3. 3.
    Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989; 83: 1930–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effect on osteoclast ultra-structure. J Clin Invest 1991; 88: 2095–105.Google Scholar
  5. 5.
    Heaney RP. The bone remodeling transient: Implication for the interpretation of clinical studies of bone mass changes. J Bone Miner Res 1994; 9: 1515–23.PubMedCrossRefGoogle Scholar
  6. 6.
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas P. Comparison of new biochemical markers of bone turnover in postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693–700.PubMedCrossRefGoogle Scholar
  7. 7.
    Chavassieux PM, Arlot ME, Reda C, Weil L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475–80.PubMedCrossRefGoogle Scholar
  8. 8.
    Gatti D, Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging 1999; 15: 285–96.PubMedCrossRefGoogle Scholar
  9. 9.
    De Groen PC, Lubbe DF, Hirsh LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 355: 1016–21.CrossRefGoogle Scholar
  10. 10.
    Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging Clin Exp Res 2000; 12: 1–12.Google Scholar
  11. 11.
    Gordon MS, Gordon MB. Response of bone mineral density to once-weekly administration of risedronate. Endocr Pract 2002; 8: 202–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Boyce BF, Fogelman I, Ralston S, et al. Focal osteomalacia due to low-dose diphosphonate therapy in Paget’s disease. Lancet 1984; 1: 821–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Plosker GL, Goa KL. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994; 47: 945–82.Google Scholar
  14. 14.
    Adami S, Guarrera G, Salvagno G, et al. Sequential treatment of Paget’s disease with human calcitonin and dichloromethylene diphosphonate (C12MDP). Metab Bone Dis Relat Res 1984; 5: 265–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio F. Paget’s disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate. Bone 1998; 23: 543–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919–44.Google Scholar
  17. 17.
    Kanis JA, McCloskey EV, Paterson AH. Use of diphosphonates in hypercalcaemia due to malignancy. Lancet 1990; 335: 170–1.PubMedCrossRefGoogle Scholar
  18. 18.
    Wasan HS. Waxman J. Clodronate for multiple myeloma. Lancet 1993; 341: 175–6.CrossRefGoogle Scholar
  19. 19.
    Giannini S, D’Angelo A, Sartori L, Passeri G, Dalle Carbonare L, Crepaldi G. Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss. Obstet Gynecol 1996; 88: 431–6.PubMedCrossRefGoogle Scholar
  20. 20.
    McCloskey E, Selby P, de Takats D, et al. Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone 2001; 28: 310–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Filipponi P, Pedetti M, Fedeli L, et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 1995; 10: 697–703.PubMedCrossRefGoogle Scholar
  22. 22.
    Heikkinen JE, Seiander KS, Laitinen K, Arnala I, Vaananen HK. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J Bone Miner Res 1997; 12: 103–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Filipponi P, Cristallini S, Policani G, Schifini MF, Casciari C, Garinei P. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass. Bone 2000; 26: 269–74.PubMedCrossRefGoogle Scholar
  24. 24.
    Rossini M, Braga V, Gatti D, Gerardi D, Zamberlan N, Adami S. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone 1999; 24: 125–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Gnudi S, Lisi L, Fini M, Malavolta N. Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women. Int J Tissue React 2001; 23: 33–7.PubMedGoogle Scholar
  26. 26.
    Fitton A, McTavish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41: 289–318.Google Scholar
  27. 27.
    Djulbegovic B, Wheatley K, Ross J, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002; 3: CD003188.PubMedGoogle Scholar
  28. 28.
    Hultbom R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999; 19: 3383–92.Google Scholar
  29. 29.
    Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III. double-blind, comparative trial. Cancer J 2001; 7: 377–87.Google Scholar
  30. 30.
    Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ. Effect of multiple intravenous pamidronate courses in Paget’s disease of bone. Rev Rheum Engl Ed 1999; 66: 467–6.Google Scholar
  31. 31.
    Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003; 18: 610–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Lane JM. Khan SN. O’Connor WJ. et al. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop 2001; 382: 6–12.PubMedCrossRefGoogle Scholar
  33. 33.
    Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002; 17: 1057–64.PubMedCrossRefGoogle Scholar
  34. 34.
    Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate. in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994; 79: 1595–9.CrossRefGoogle Scholar
  35. 35.
    Thiebaud D, Burckhardt P, Melchior J, et al. Two years’ effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994; 4: 76–83.PubMedCrossRefGoogle Scholar
  36. 36.
    Wimalawansa SJ. Intermittent intravenous pamidronate therapy: highly effective treatment for postmenopausal osteoporosis. J Bone Miner Res 2000; 16(Suppl 1): S405 (Abstract).Google Scholar
  37. 37.
    McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 1987; 8(Suppl 1): S35–41.PubMedGoogle Scholar
  38. 38.
    O’Rourke NP, McCloskey EV, Rosini S, Coleman RE, Kanis JA. Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). Br J Cancer 1994; 69: 914–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Delmas PD, Chapuy MC, Edouard C, Meunier PJ. Beneficial effects of aminohexane diphosphonate in patients with Paget’s disease of bone resistant to sodium etidronate. Am J Med 1987; 83: 276–82.PubMedCrossRefGoogle Scholar
  40. 40.
    Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio F. Paget’s disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate. Bone 1998; 23: 543–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Adami S, Bevilacqua M, Broggini M, et al. Short-term intravenous therapy with Neridronate in Paget’s disease. Clin Exp Rheumatol 2002; 20: 55–8.PubMedGoogle Scholar
  42. 42.
    Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003; 18: 126–30.PubMedCrossRefGoogle Scholar
  43. 43.
    Tobias JH, Laversuch CJ, Chambers TJ, Gallagher AC. Aminohexane bisphosphonate suppresses bone turnover in postmenopausal women more rapidly than oestrogen-gestagen therapy. Br J Rheumatol 1996; 35: 636–41.PubMedCrossRefGoogle Scholar
  44. 44.
    Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 2000; 15: 599–604.PubMedCrossRefGoogle Scholar
  45. 45.
    Braga V, Gatti D, Bakri J, Fracassi E, Adami S. Intravenous cyclical neridronate in the treatment of postmenopausal osteoporosis. Bone 2002; 30(Suppl 3): S31 (Abstract).Google Scholar
  46. 46.
    Filipponi P, Cristallini S, Frediani B, Policani G, Schifini MF, Garinei P. Two years neridronate increases bone mineral density in postmenopausal women affected by osteoporosis. Bone 2002; 30(Suppl 3): S48 (Abstract).Google Scholar
  47. 47.
    Dooley M, Balfour JA. Ibandronate. Drugs 1999; 57: 101–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 1996; 11: 587–93.PubMedCrossRefGoogle Scholar
  49. 49.
    van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698–705.PubMedCrossRefGoogle Scholar
  50. 50.
    Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99: 2509–17.PubMedCrossRefGoogle Scholar
  51. 51.
    Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997; 75: 295–300.PubMedCrossRefGoogle Scholar
  52. 52.
    Menssen HD, Sakalova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002; 20: 2353–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Woitge HW, Oberwittler H, Heichel S, Grauer A, Ziegler R, Seibel MJ. Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. Clin Chem 2000; 46: 684–90.PubMedGoogle Scholar
  54. 54.
    Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996; 19: 527–33.PubMedCrossRefGoogle Scholar
  55. 55.
    Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001; 16: 1871–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103: 298–307.PubMedCrossRefGoogle Scholar
  57. 57.
    Recker RR, Stakkestad JA, Felsenbers D, et al. A new treatment paradigm: Quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): Results of a 3-year trial. Osteoporos Int 2000; 11(Suppl 1): S209 (Abstract).Google Scholar
  58. 58.
    Adami S, Christiansen C, Burdeska A, Coutant K, Mahoney P. Three-monthly 2 mg intravenous ibandronate injections restore bone turnover to premenopausal levels. J Bone Miner Res 2002; 17(Suppl 1): S472 (Abstract).Google Scholar
  59. 59.
    Burckhardt P, Hüsi B, Thiébaud D, Jacquet A-F. Long term effect of a single dose of intravenous Ibandronate. J Musculoskel Neuron Interact 2003; 3: 77–82.Google Scholar
  60. 60.
    Stakkestad JA, Skag A, Nordby A, Burdeska A, Jonkanski I, Meinert R. Three-monthly intravenous ibandronate bolus injections: A novel treatment regimen to prevent postmenopausal bone loss. Osteoporos Int 2002; 13(Suppl 1): S17 (Abstract).Google Scholar
  61. 61.
    Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42446. a new. potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745–51.CrossRefGoogle Scholar
  62. 62.
    Widler L, Jaeggi KA, Glatt M, et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002; 45: 3721–38.PubMedGoogle Scholar
  63. 63.
    Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191–200.PubMedCrossRefGoogle Scholar
  64. 64.
    Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III. double-blind, comparative trial. Cancer J 2001; 7: 377–87.Google Scholar
  65. 65.
    Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–68.PubMedCrossRefGoogle Scholar
  66. 66.
    Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20(Suppl 2): 45–54.PubMedCrossRefGoogle Scholar
  67. 67.
    Chung G. Keen RW. Zoledronate treatment in active Paget’s disease. Ann Rheum Dis 2003; 62: 275–6.CrossRefGoogle Scholar
  68. 68.
    Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653–61.PubMedCrossRefGoogle Scholar
  69. 69.
    Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41: 326–31.PubMedCrossRefGoogle Scholar
  70. 70.
    Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Löwik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget’s disease with the nitrogen-containing bisphosphonate dimethylaminohy-droxypropylidene bisphosphonate. J Bone Miner Res 1995; 10: 956–62.PubMedCrossRefGoogle Scholar
  71. 71.
    Passeri M, Baroni MC, Pedrazzoni M, et al. Intermittent treatment with intravenous 4-amino-l-hydroxybutilydene-l,l-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991; 15: 237–48.PubMedCrossRefGoogle Scholar
  72. 72.
    Frost HM. Treatment of osteoporosis by manipulation of coherent bone cell population. Clin Orthop Rel Res 1979; 143: 227–44.Google Scholar
  73. 73.
    Anderson C, Cape RD, Crilly RG, et al. Preliminary observation of a form of coherence therapy for osteoporosis. Calcif Tissue Int 1984; 36: 341–3.PubMedCrossRefGoogle Scholar
  74. 74.
    Turner CH. Yield behaviour of cancellous bone. J Biomech Eng 1989; 111: 1–5.CrossRefGoogle Scholar
  75. 75.
    Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 338: 736–46.Google Scholar
  76. 76.
    Marshall D, Johnell O, Wedell H. Meta analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Hockberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999; 42: 1246–54.CrossRefGoogle Scholar
  78. 78.
    Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041): 1535–41.Google Scholar
  80. 80.
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077–82.PubMedCrossRefGoogle Scholar
  81. 81.
    Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83–91.CrossRefGoogle Scholar
  82. 82.
    Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–52.Google Scholar
  83. 83.
    Van Daele PLA, Seibel MJ, Burger H, et al. Case-control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. BMJ 1996; 312: 482–3.PubMedCrossRefGoogle Scholar
  84. 84.
    Landman JO, Hamdy NAT, Pawels EKJ, et al. Skeletal metabolism in patients with osteoporosis after discontinuation of long term treatment with oral pamidronate. J Clin Endocrinol Metab 1995; 80: 3465–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Stock JL, Bell NH, Chesnut CH III, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997; 103: 291–7.PubMedCrossRefGoogle Scholar
  86. 86.
    Lauren L, Osterman T, Karhi T. Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats. Pharmacol Toxicol 1991; 69: 365–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Adami S. Zamberlan N. Adverse effects of bisphosphonates. Drug Safety 1996; 14: 158–60.CrossRefGoogle Scholar

Copyright information

© Springer Internal Publishing Switzerland 2003

Authors and Affiliations

  • Leonardo Sartori
    • 1
    • 2
  • Silvano Adami
    • 3
  • Paolo Filipponi
    • 4
  • Gaetano Crepaldi
    • 1
    • 2
  1. 1.Clinica Medica I, Department of Medical and Surgical SciencesUniversity of PadovaPadovaItaly
  2. 2.Center for the Study of AgingNational Research CouncilPadova
  3. 3.Rheumatological RehabilitationUniversity of VeronaVerona
  4. 4.Metabolic Section, Department of Internal Medicine, Pathology and PharmacologyPerugia UniversityPerugiaItaly

Personalised recommendations